{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T05:27:39Z","timestamp":1777008459904,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ad.2025.05.016","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T11:46:04Z","timestamp":1748432764000},"page":"T731-T739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies"],"prefix":"10.1016","volume":"116","author":[{"given":"I.","family":"Rivera-Ruiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gil-Villalba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.J.","family":"Navarro-Trivi\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2025.05.016_bib0310","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clindermatol.2019.10.003","article-title":"Contact dermatitis: a great imitator","volume":"38","author":"Elmas","year":"2020","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0315","first-page":"277","article-title":"Contact dermatitis \u2013 epidemiological study","volume":"6","author":"Statescu","year":"2011","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.ad.2025.05.016_bib0320","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.det.2020.02.001","article-title":"Occupational contact dermatitis: evaluation and management considerations","volume":"38","author":"Hollins","year":"2020","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.ad.2025.05.016_bib0325","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ad.2017.05.011","article-title":"Dermatitis de contacto al\u00e9rgica por regiones anat\u00f3micas. Claves diagn\u00f3sticas","volume":"109","author":"Rozas-Mu\u00f1oz","year":"2018","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.016_bib0330","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/cod.13119","article-title":"Prevalence of contact allergy in the general population: a systematic review and meta-analysis","volume":"80","author":"Alinaghi","year":"2019","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0335","first-page":"181","article-title":"Contact dermatitis: etiologies of the allergic and irritant type","volume":"25","author":"Rubins","year":"2020","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"key":"10.1016\/j.ad.2025.05.016_bib0340","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/DER.0000000000000654","article-title":"Usefulness of patch testing with patient's own products in the diagnosis of allergic contact dermatitis","volume":"32","author":"Tous-Romero","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/cod.13584","article-title":"Review of biologics in allergic contact dermatitis","volume":"83","author":"Bhatia","year":"2020","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0350","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/DER.0000000000000726","article-title":"Patch testing during immunosuppressive therapy: a systematic review","volume":"32","author":"Mufti","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0355","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/cod.13833","article-title":"European Surveillance System on Contact Allergies (ESSCA): characteristics of patients patch tested and diagnosed with irritant contact dermatitis","volume":"85","author":"Loman","year":"2021","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0360","article-title":"Advancing the understanding of allergic contact dermatitis: from pathophysiology to novel therapeutic approaches","volume":"10","author":"Tramontana","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ad.2025.05.016_bib0365","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mcna.2019.08.012","article-title":"Allergic contact dermatitis","volume":"104","author":"Nassau","year":"2020","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ad.2025.05.016_bib0370","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1111\/all.14989","article-title":"Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants","volume":"76","author":"Lefevre","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.ad.2025.05.016_bib0375","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jaci.2014.03.009","article-title":"Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response","volume":"134","author":"Dhingra","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ad.2025.05.016_bib0380","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/DER.0000000000000435","article-title":"Systemic treatments for allergic contact dermatitis","volume":"30","author":"Sung","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0385","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.ad.2025.05.016_bib0390","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ad.2020.12.003","article-title":"Inhibidores de JAK: usos en dermatolog\u00eda. Parte 1: generalidades, aplicaciones en vit\u00edligo y en alopecia areata","volume":"112","author":"Garcia-Melendo","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.016_bib0395","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ad.2020.12.006","article-title":"Inhibidores de JAK: usos en dermatolog\u00eda. Parte 2: aplicaciones en psoriasis, dermatitis at\u00f3pica y otras dermatosis","volume":"112","author":"Garc\u00eda-Melendo","year":"2021","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.016_bib0400","doi-asserted-by":"crossref","DOI":"10.12788\/cutis.0705","article-title":"Janus kinase inhibitors: a promising therapeutic option for allergic contact dermatitis","volume":"111","author":"Johnson","year":"2023","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.016_bib0405","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jdermsci.2016.09.007","article-title":"JAK inhibitor JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation","volume":"84","author":"Amano","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.ad.2025.05.016_bib0410","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/cod.14204","article-title":"Occupational airborne allergic contact dermatitis to invasive Compositae species treated with abrocitinib: a case report","volume":"87","author":"Baltazar","year":"2022","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0415","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/cod.14234","article-title":"Tofacitinib in refractory Parthenium-induced airborne allergic contact dermatitis","volume":"88","author":"Muddebihal","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0420","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jdcr.2023.11.023","article-title":"Upadacitinib as a treatment for co-existent allergic contact dermatitis and psoriasis","volume":"44","author":"Ch\u2019en","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ad.2025.05.016_bib0425","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/cod.14278","article-title":"Sequential patch testing in a patient treated with dupilumab then with upadacitinib: differences in patch test results as well as in disease control","volume":"88","author":"Mainville","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0430","first-page":"341","article-title":"A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis","volume":"11","author":"Volf","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0435","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ad.2023.09.005","article-title":"Roflumilast t\u00f3pico y oral en dermatolog\u00eda Una revisi\u00f3n narrativa","volume":"115","author":"Mansilla-Polo","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.ad.2025.05.016_bib0440","doi-asserted-by":"crossref","first-page":"139","DOI":"10.36849\/JDD.7295","article-title":"The safety and efficacy of roflumilast cream 0.15% and 0.05% in patients with atopic dermatitis: randomized, double-blind phase 2 proof of concept study","volume":"22","author":"Gooderham","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0445","year":"2016"},{"key":"10.1016\/j.ad.2025.05.016_bib0450","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/DER.0000000000000488","article-title":"Allergic contact dermatitis to crisaborole","volume":"30","author":"Kimyon","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0455","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/cod.14389","article-title":"Contact allergy to crisaborole in a paediatric patient with atopic dermatitis","volume":"89","author":"Arora","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0460","doi-asserted-by":"crossref","DOI":"10.1177\/03000605231169445","article-title":"Difamilast for the treatment of atopic dermatitis","volume":"51","author":"Freitas","year":"2023","journal-title":"J Int Med Res"},{"key":"10.1016\/j.ad.2025.05.016_bib0465","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/DER.0000000000000616","article-title":"T helper 2 inhibitors in allergic contact dermatitis","volume":"32","author":"Ludwig","year":"2021","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0470","unstructured":"The effects of dupilumab on allergic contact dermatitis. ClinicalTrials.gov ID NCT03935971."},{"key":"10.1016\/j.ad.2025.05.016_bib0475","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/bjd\/ljad156","article-title":"Efficacy and safety of dupilumab in patients with severe chronic hand eczema with inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled phase IIb proof-of-concept study","volume":"189","author":"Voorberg","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0480","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaad.2021.02.044","article-title":"Effect of dupilumab on allergic contact dermatitis and patch testing","volume":"84","author":"Jo","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0485","doi-asserted-by":"crossref","first-page":"158","DOI":"10.12788\/cutis.0471","article-title":"Patch testing on dupilumab: reliable or not?","volume":"109","author":"Kuzyk","year":"2022","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.016_bib0490","first-page":"265","article-title":"Dupilumab for allergic contact dermatitis: an overview of its use and impact on patch testing","volume":"109","author":"Johnson","year":"2022","journal-title":"Cutis"},{"key":"10.1016\/j.ad.2025.05.016_bib0495","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jaad.2023.10.029","article-title":"Impact of dupilumab on patch test results and allergic contact dermatitis: a prospective multicenter study","volume":"90","author":"Bocquel","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0500","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1111\/jdv.18099","article-title":"Dupilumab for the treatment of refractory allergic contact dermatitis from rubber\/latex concomitant with atopic dermatitis","volume":"36","author":"Koh","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ad.2025.05.016_bib0505","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cod.13545","article-title":"Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones","volume":"83","author":"Ruge","year":"2020","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0510","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/cod.14367","article-title":"Follow-up of patch test reactivity to sesquiterpene lactone mix in a patient successfully treated with dupilumab for severe airborne allergic contact dermatitis","volume":"89","author":"Gallo","year":"2023","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0515","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.36849\/JDD.6246","article-title":"Chromate-induced allergic contact dermatitis treated with dupilumab","volume":"20","author":"Wilson","year":"2021","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0520","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/ajd.13740","article-title":"Treatment of generalised isobornyl acrylate contact allergy from diabetes pump with dupilumab","volume":"63","author":"Arasu","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0525","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/DER.0000000000000446","article-title":"Dupilumab for systemic allergy syndrome with dermatitis","volume":"30","author":"Jacob","year":"2019","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0530","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/derm.2022.0023","article-title":"Patch testing in patients with severe atopic dermatitis treated with dupilumab: a multicentric approach in Spain","volume":"34","author":"Docampo-Sim\u00f3n","year":"2023","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0535","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1159\/000524380","article-title":"Occupational chronic contact dermatitis successfully treated with dupilumab: a case series","volume":"238","author":"Slodownik","year":"2022","journal-title":"Dermatology"},{"key":"10.1016\/j.ad.2025.05.016_bib0540","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/occmed\/kqaa152","article-title":"Mixed occupational and iatrogenic allergic contact dermatitis in a hairdresser","volume":"70","author":"Koblinski","year":"2020","journal-title":"Occup Med (Lond)"},{"issue":"Suppl. 2","key":"10.1016\/j.ad.2025.05.016_bib0545","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2025.05.016_bib0550","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/cod.12043","article-title":"CD4(+) T cells producing interleukin (IL)-17, IL-22 and interferon-\u03b3 are major effector T cells in nickel allergy","volume":"68","author":"Dyring-Andersen","year":"2013","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0555","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/cod.12988","article-title":"The effect of treatment with anti-interleukin-17 in patients with allergic contact dermatitis","volume":"78","author":"Todberg","year":"2018","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0560","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4161\/mabs.3.6.17815","article-title":"Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders","volume":"3","author":"Benson","year":"2011","journal-title":"MAbs"},{"key":"10.1016\/j.ad.2025.05.016_bib0565","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.4049\/jimmunol.0901767","article-title":"IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes","volume":"184","author":"Pennino","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.ad.2025.05.016_bib0570","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1600-0536.2011.01907.x","article-title":"Lack of effect of ustekinumab in treatment of allergic contact dermatitis","volume":"65","author":"Bangsgaard","year":"2011","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0575","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ad.2025.05.016_bib0580","first-page":"287","article-title":"Occupational wheat contact dermatitis and treatment with omalizumab","volume":"23","author":"Mur Gimeno","year":"2013","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.ad.2025.05.016_bib0585","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaad.2008.02.016","article-title":"Patch testing a patient with allergic contact hand dermatitis who is taking infliximab","volume":"59","author":"Rosmarin","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2025.05.016_bib0590","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/DER.0000000000000056","article-title":"Patch test results in psoriasis patients on biologics","volume":"25","author":"Kim","year":"2014","journal-title":"Dermatitis"},{"key":"10.1016\/j.ad.2025.05.016_bib0595","first-page":"103","article-title":"Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis","volume":"136","author":"Piguet","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ad.2025.05.016_bib0600","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/205873920601900125","article-title":"Infliximab in recalcitrant severe atopic eczema associated with contact allergy","volume":"19","author":"Cassano","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ad.2025.05.016_bib0605","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/1521-4141(200211)32:11<3326::AID-IMMU3326>3.0.CO;2-9","article-title":"Consequences of OX40\u2013OX40 ligand interactions in Langerhans cell function: enhanced contact hypersensitivity responses in OX40L-transgenic mice","volume":"32","author":"Sato","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ad.2025.05.016_bib0610","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","article-title":"OX40 in the pathogenesis of atopic dermatitis \u2013 a new therapeutic target","volume":"25","author":"Croft","year":"2024","journal-title":"Am J Clin Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102500376X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000173102500376X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T08:01:40Z","timestamp":1753084900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000173102500376X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S000173102500376X"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.016","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Exploring New Horizons in Allergic Contact Dermatitis Treatment: The Role of Emerging Therapies","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2025.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2024.10.068","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}